Skip to main content
Top
Published in: Breast Cancer Research 2/2000

01-04-2000 | Review

Transforming growth factor-β and breast cancer: Introduction

Author: Joyce Slingerland

Published in: Breast Cancer Research | Issue 2/2000

Login to get access

Excerpt

The balance between growth stimulatory and growth inhibitory signals is essential for normal tissue homeostasis. An imbalance of these signals may favour the development of uncontrolled proliferation, leading to neoplasia. Transforming growth factor (TGF)-β plays an important role in the regulation of mammary duct development and cellular proliferation in the mammary gland during adult life. The different in vitro and in vivo models that have shed light on mammary development and the limitations of these models are presented in the first review of this series. The second article reviews murine models that have provided insights, not only into the role of TGF-β in mammary development, but also into its role in tumour suppression. TGF-β receptors and the Smad signalling molecules transduce TGF-β signals. The study of these has yielded important insights into the regulation of this pathway. A review of the many levels at which TGF-β signalling can be disrupted during oncogenesis is presented in this series. TGF-β is a potent mediator of G1 arrest in mammary epithelial and other cell types. Mechanisms of G1 arrest by TGF-β and their dysregulation in cancers are addressed. In a final review, the tumor promoting effects of TGF-β are discussed. In advanced stages of breast cancer, not only is the cell cycle arrest response to TGF-β lost, but, in addition, this pathway can be subverted in such a way that TGF-β signalling indirectly supports tumour viability, invasiveness and malignant progression. …
Metadata
Title
Transforming growth factor-β and breast cancer: Introduction
Author
Joyce Slingerland
Publication date
01-04-2000
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 2/2000
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr39

Other articles of this Issue 2/2000

Breast Cancer Research 2/2000 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine